Accuray Appoints Steve La Neve as CEO, Signaling Growth and Innovation Ahead

Accuray's Leadership Shift Paves the Way for Growth and Innovation

Accuray Incorporated undergoes a significant leadership change as it announces the appointment of Steve La Neve as the new Chief Executive Officer, effective October 20, 2025. La Neve succeeds Suzanne Winter, who retires after six successful years but will remain involved until the end of November to ensure a smooth transition. This leadership transition is part of a broader organizational transformation aimed at enhancing operational performance and competitiveness in the medical technology sector. The Board of Directors, led by Chairman Joe Whitters, emphasizes that these changes are crucial to advancing the company's growth strategy and adapting to the evolving market landscape.

La Neve arrives at Accuray with over 40 years of extensive experience in international medical technology, having held significant leadership positions in companies such as Globus Medical Inc., Bone Biologics Corporation, and Medtronic. His appointment signals a strategic shift as Accuray aims to leverage his experience to bolster its operational agility and increase operating margins during the current fiscal year. La Neve expresses enthusiasm for Accuray's mission to deliver impactful radiation therapy solutions. He notes the company's robust installed base and strong order backlog, which he believes positions Accuray favorably for growth in rapidly expanding markets, particularly in the oncology space.

In addition to La Neve's appointment, Accuray strengthens its leadership team with the nomination of Chan W. Galbato to the Board of Directors and the designation of Steven F. Mayer as Transformation Board Sponsor. These moves highlight Accuray's commitment to driving execution and fostering a customer-centric organization. With a renewed focus on innovation and strategic operational enhancements, the company aims to solidify its market presence and continue delivering state-of-the-art solutions in radiation therapy, ensuring it remains a key player in the medical technology industry.

In light of these developments, Accuray's new leadership team is poised to tackle the challenges of the competitive landscape. The strategic initiatives set for implementation not only aim to improve operational efficiency but also to reinforce Accuray's dedication to developing cutting-edge medical technologies that enhance patient care. As the company embarks on this transformation journey, stakeholders are optimistic about the potential for growth and improved outcomes in the healthcare sector.